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Paintingsed as sites for the assembly of a number of viruses and are considered to play a
major role in pseudotyping events. As a consequence, host glycosylphosphatidylinositol (GPI) anchored
proteins commonly associated with lipid rafts can be found being incorporated into viral lipid envelopes with
beneﬁcial consequences for viral replication. In this review we will look at the link between lipid rafts, GPI-
anchored proteins and retroviral particles and how these relationships can be exploited for the modiﬁcation
of enveloped viruses.
© 2008 Elsevier Inc. All rights reserved.The lipid raft hypothesisAs late addendum to the ﬂuid mosaic model of biological
membranes, which describes cellular membranes as a sea of lipid
molecules with ﬂoating protein entities, lipid rafts (LR) have caused
quite some waves in the scientiﬁc community and the biological
relevance and conditions of their existence remain highly disputed
(Hancock, 2006; Hanzal-Bayer and Hancock, 2007; Michel and
Bakovic, 2007; Shaw, 2006). LRs are membrane sub-structures or
microdomains enriched for cholesterol and sphingolipids. According
to the original LR hypothesis (Simons and Ikonen, 1997), formation of
these microdomains occurs as a consequence of the different
biophysical properties of lipids found in the plasma membrane
which also have different propensities for association with one
another, leading to “phase-separation” events. Supporting evidence
for phase separation comes from the in vitro study of model
membranes which indeed demonstrated that mixtures of cholesterol,
sphingolipids and unsaturated phospholipids induce the formation of
macroscopic domains of different lipid composition (Brown and
London, 1998; Radhakrishnan and McConnell, 1999). Similar events
are thought to occur in vivo, resulting in LR formation. However,
application of advanced imaging technologies to the topic (Kenworthy,(C. Metzner),
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l rights reserved.Petranova, and Edidin, 2000; Kusumi et al., 2005; Mayor and Rao,
2004; Plowman et al., 2005; Sharma et al., 2004; Zacharias et al.,
2002) showed that although they could not disprove the existence of
lipid rafts, modiﬁcations of the original hypothesis were called for. In
summary, these experiments suggested highly dynamic lipid rafts
with short half lives and of very limited spatial dimensions, being
strongly inﬂuenced by their protein content. LR size was estimated to
be between 5 and 20 nm (Prior et al., 2003; Sharma et al., 2004), which
would only have very limited space for associated proteins i.e. 3–5
molecules per LR and half lives were estimated in the 100 nm range
(Kawasaki et al., 2001; Kusumi et al., 2004). Additionally, the
association of different protein species depending on cell type will
severely change the characteristics of LRs such as their spatial
dimensions and half lives (Hancock, 2006). Two main roles have
been proposed regarding the physiological functions of LRs: (i) the re-
arrangement and trafﬁcking of membranes and associated proteins
(Hanzal-Bayer and Hancock, 2007) and (ii) facilitating signal transduc-
tion (Gupta and DeFranco, 2007; Jury et al., 2007; Patra, 2008). LR
protein content is inherently linked to their functions and different
types of proteins can be found to be enriched in lipid rafts, most
prominently the glycosylphosphatidylinositol (GPI) anchored proteins
(Brown, 1992; Legler et al., 2005; Paulick and Bertozzi, 2008).
Lipid rafts and GPI-anchored proteins
GPI-anchored proteins are membrane associated after post-
translational modiﬁcation and predominantly found on the external
126 Minireviewside of the cell membrane, with signiﬁcant amounts also located in
intracellular membrane domains (Orlean and Menon, 2007; Paulick
and Bertozzi, 2008). Proteins targeted for GPI anchoring contain a GPI
signalling sequence (GSS) at the C-terminal end and addition of this
feature to previously non-GPI-anchored proteins transforms them
efﬁciently into GPI-anchored proteins (Brodsky et al., 1994; Brunsch-
wig et al., 1999; Cordy et al., 2003; Jones and Geraghty, 2004; Kueng
et al., 2007; Legler et al., 2005; Skountzou et al., 2007) (see Table 1),
displaying properties typical of GPI-anchored proteins. The GSS is
recognised in the endoplasmatic reticulum (ER) by the transamidase
enzyme complex and is replaced by the preformed GPI anchor. GPI-
anchored proteins share a common backbone structure, consisting of a
phosphoethanolamine group next to the protein, followed by
mannose residues, a non-acetylated glucosamine and a phosphoino-
sitol moiety, which in turn is associated to the lipid residues
responsible for membrane anchoring (Orlean and Menon, 2007).
GPI-anchored proteins have a variety of different functions (Paulick
and Bertozzi, 2008) from complement regulatory activity to signal
transduction (see Table 1). GPI proteins can also be found in serum and
other body ﬂuids both with intact or absent GPI anchors (Landi et al.,
2003). They are released from the plasma membrane to the
surrounding milieu by a process termed shedding. Shedding can be
induced by the activity of enzymes speciﬁc for cleavage of inositol
phospholipids which remove parts of the GPI anchor (Lauc and Heffer-
Lauc, 2006). Additionally, shedding can also be induced by the
formation of membrane vesicles from intact cells (van Niel et al., 2001;
Wolfers et al., 2001) and also by formation of small aggregates that
may contain a small number of cellular lipid molecules in addition to
few molecules of the GPI-anchored protein (Rooney et al., 1996).
Processes that release GPI-linked proteins into themediumwith intact
GPI anchors are reversible and it has been shown in a variety of in vitro
and in vivo systems that GPI-linked proteins can be re-inserted into
cell membranes (Dunn et al., 1996; Kooyman et al., 1995; Rifkin and
Landsberger, 1990; Rooney et al., 1993; Rooney et al., 1996; Vakeva
et al., 1994). Therefore, GPI-anchored proteins can be considered to be
“hypermobile”. The physiological functions of GPI-anchored protein
mobility are poorly deﬁned, however shedding of GPI-anchoredTable 1
Endogenous and recombinant GPI-anchored proteins
Endogenous GPI-anchored proteins serve a variety of different functions. In addition, non G
proteins without losing the function of the endogenous protein (LPS, lipopolysaccharide; LPB
receptor 3; GM-CSF, granulocyte-macrophage colony stimulating factor).proteins could lead to a more systemic effect of the GPI-linked
proteins or to activation events upon release.
Lipid rafts in virology
One interesting element of LRs is their apparent association with
aspects of virus biology (for a summary see Table 2). They have been
proposed as sites for entry and exit of a number of different virus
species (Chazal and Gerlier, 2003; Suzuki and Suzuki, 2006;
Wilﬂingseder and Stoiber, 2007). Involvement of LRs in the entry of
virus particles to cells has been demonstrated for the non-enveloped
SV40 (Papovaviridae) (Anderson et al., 1998; Gilbert et al., 2005;
Norkin et al., 2002; Parton and Lindsay, 1999; Pelkmans et al., 2001;
Stang et al., 1997; Tsai et al., 2003), rotavirus (Reoviridae) (Arias et al.,
2002; Guerrero et al., 2002), rhinovirus (Picornaviridae) (Grassme et
al., 2005), human adenovirus (Colin et al., 2005), entero- (Bergelson et
al., 1994; Karnauchow et al., 1996; Stuart et al., 2002) and echovirus
(Marjomaki et al., 2002) as well as the enveloped inﬂuenza virus
(Orthomyxoviridae) (Lakadamyali et al., 2004; Sieczkarski and Whit-
taker, 2002), human immunodeﬁciency virus type 1 (HIV-1, Retro-
viridae) (Fantini et al., 1993; Hammache et al., 1998; Janes et al., 1999;
Kozak et al., 2002; Puri et al., 1998) and members of the families
herpesviridae (Bender et al., 2003; Cherukuri et al., 2004; Desplan-
ques et al., 2008; Fingeroth et al., 1984; Lee, Church, andWilson, 2003;
Lyman et al., 2008; Tang et al., 2008), ﬁloviridae (Aman et al., 2003;
Bavari et al., 2002) and ﬂaviviridae (Medigeshi et al., 2008). Most likely
this is due to cellular receptors or co-receptors for virus entry being
located in LRs, e.g. CD4 and CCR5 in the case of HIV-1 (Manes et al.,
1999; Xavier et al., 1998). However, for other viruses which require LRs
for entry, such as herpes simplex virus (HSV) cellular receptors are not
primarily found in LRs (Bender et al., 2003).
Assembly and exit (or budding) of virus particles is also associated
with LRs (Table 2). For non-enveloped viruses only rotavirus assembly
has been shown to be associated with membrane microdomains
(Delmas et al., 2004; Sapin et al., 2002). However, a range of enveloped
viruses seems to use LRs as a platform for assembly and/or budding of
viral particles, amongst themmeasles virus (Paramyxoviridae) (ManiePI-anchored proteins can be genetically engineered to yield recombinantly anchored
, LPS binding protein; TRAIL-R3, tumor necrosis factor-related apoptosis-inducing ligand
Table 2
Lipid rafts in virology
A variety of both naked and enveloped viruses is associated with lipid rafts or lipid raft components during viral exit or entry. The table provides a summary of these interactions.
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Paramyxoviridae) (Brown et al., 2002; Marty et al., 2004; McDonald
et al., 2004), Sendai virus (Paramyxoviridae) (Ali and Nayak, 2000),
Marburg and Ebola virus (Filoviridae) (Bavari et al., 2002; Panchal
et al., 2003), vesicular stomatitis virus (VSV, Rhabdoviridae) (Brown
and Lyles, 2003) and inﬂuenza virus (Orthomyxoviridae) (Barman and
Nayak, 2000; Scheiffele et al., 1997; Zhang et al., 2000). In the family
retroviridae, it was suggested that HIV assembles and buds through
interactions with LRs (Chazal and Gerlier, 2003; Lindwasser and Resh,
2002; Nguyen and Hildreth, 2000; Ono and Freed, 2001;Wilﬂingseder
and Stoiber, 2007). Additionally, LRs have also been implicated in
assembly and budding of gammaretroviridae e.g. murine leukemia
virus (MLV) and may be central to pseudotyping events e.g. the
presentation of VSV-G proteins on the envelopes of MLV-derived viral
particles (Briggs et al., 2003; Pickl et al., 2001). Pickl et al.
demonstrated the co-localisation of viral proteins to LR markers and
could identify these markers in viral membrane preparations.
Additionally, proteins known to be associated to LRs (c-Src, c-Ras)
were incorporated into virus particles, whereas proteins excluded
from LRs were not found in viral particles (Pickl et al., 2001). They
concluded that enveloped viruses employ membrane microdomains
for particle assembly and budding, but more importantly, that the
localisation of viral components to LRs is essential for pseudotyping
events i.e. due to the propensity of different viral envelope
glycoproteins for LRs they can be co-packaged into viral particles
(Pickl et al., 2001). The ﬁnding that even phylogenetically distinct
virus proteins like the VSV-G can be used for pseudotyping of
retroviral particles may be explained by the fact that envelope
proteins of different virus genera share the afﬁnity for membrane
microdomains. As well as the concept of LRs, their involvement in the
life cycle of viruses is also controversial. One interesting approach to
tackle this problem is comparative proteomics, extending the studies
mentioned above by Pickl et al. Comparison of the protein content of
cellular LR preparation and the protein content of viruses derived from
these cells could help to ﬁnd similarities and thus generate a linkbetween LRs and viral budding. First efforts have been made to deﬁne
the proteome of both LRs (Foster and Chan, 2007; Foster et al., 2003)
and viral particles (Chung et al., 2006; Maxwell and Frappier, 2007;
Saphire et al., 2006), however, extensive comparative information
would be interesting.
Modiﬁcation of retroviral vectors using GPI-anchored proteins
The ﬁrst suggestion to use GPI-anchored proteins for the
modiﬁcation of retroviral vectors may have well come from the
ﬁndings that different retroviral species, most prominently HIV-1,
incorporate GPI-anchored proteins, like the complement regulatory
factors CD55 and CD59 during budding. Viral particles beneﬁt from
these incorporated host factors as they show increased resistance to
complement activity (Saifuddin et al., 1997). Both primary HIV-1
isolates and virus isolates derived from virus producing cell lines were
shown to activate the complement cascade, however, levels of
complement-mediated virolysis were low (Banki et al., 2005; Stoiber
et al., 2008). When virus was produced from cell lines signiﬁcantly
lower levels of virolysis were seen after over-expression of CD59 and
CD55 (Saifuddin et al., 1997) indicating the complement-protective
activity of the acquired proteins. The transfer of this phenomenon to
MLV-derived viral particles by over-expression of CD59 in virus
producer cell lines (Breun et al., 1999) constitutes a ﬁrst attempt to use
GPI-anchored proteins for the modiﬁcation of retroviral vectors (RVs).
Expression of GPI-anchored proteins in virus producing cells and
subsequent insertion into budding viral particles (Breun et al., 1999;
Kueng et al., 2007; Skountzou et al., 2007) – potentially fuelled by the
co-localisation of GPI-anchored proteins with sites of virus assembly
and/or budding in LRs (see Fig. 1, left) – is the ﬁrst of two ways to
modify enveloped retroviral vectors with GPI-anchored proteins.
Additionally, puriﬁed GPI-anchored proteins can be re-inserted into
viral envelopes in a process termed “viral painting” post-budding
(Metzner et al., 2008) (see Fig. 1, right) without the need for genetic
modiﬁcation of virus producing cells and independent of any
Fig. 1. Modiﬁcation of retroviral vectors with GPI-anchored proteins. GPI-anchored proteins can be used to modify retroviral vectors using two different routes. Classically,
transfection of retroviral producer cell lines leads to the production of modiﬁed virions (left). Co-localisation of GPI-anchored proteins with sites of viral budding – i.e. at lipid rafts –
leads to the incorporation of the GPI protein into viral particles. Additionally, re-insertion of puriﬁed GPI-anchored proteins (“viral painting”) to viral proteins exploits the afﬁnity of
the lipophilic GPI anchor to the viral envelope.
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non GPI-anchored proteins can be genetically engineered to become
GPI-anchored proteins, this makes them interesting targets for
modiﬁcation of retroviral and other enveloped virus vectors.
Modiﬁcation of retroviral vectors by transfection of virus
producer cell lines
Co-transfection of plasmid vectors carrying genes for the produc-
tion of RVs with constructs expressing the GPI-anchored proteins
(Kueng et al., 2007; Skountzou et al., 2007) or super-transfection of
pre-existing virus producing cell lines (Breun et al., 1990) leads to the
formation of viral particles presenting GPI-anchored molecules on
their envelopes. These particles acquire novel properties as a
consequence of the incorporation of the GPI-anchored protein.
In 1999, Breun et al. demonstrated that super-transfection of the
retroviral producer cell line PALSG/S, which is based on the murine
NIH3T3 cells, with the human GPI-anchored protein CD59, yields viral
particles that are resistant to the activity of complement in serum
(Breun et al., 1999). Incorporation of CD59 in viral particles was shown
and infectious titers of CD59 protected virus were increased up to 100-
fold. These results suggested for the ﬁrst time that incorporation of
recombinantly expressed GPI proteins into the envelopes of viral
particles is possible and that these modiﬁcations can be useful for
gene therapy approaches. Interestingly, even viral vectors produced
from human cell lines are partially susceptible to complement activity,
due to the fact that viral proteins themselves interact with proteins of
the complement system and can initiate complement activity. There-
fore, production of RV from human cells does not completely
circumvent the need for complement protection.
More recently, two studies have used co-transfection approaches
to produce virus-like particles (VLPs) displaying GPI-anchored
molecules in mammalian (Kueng et al., 2007) and insect cells
(Skountzou et al., 2007). In both cases, recombinant GPI-anchored
proteins were generated from different cytokine species and tested for
their functional properties, compared to their soluble counterparts, in
order to achieve different goals. Whereas Kueng et al. could
demonstrate that the GPI-anchored cytokines can elicit cellular
responses such as differentiation and proliferation with similar
efﬁciency as the soluble cytokines, Skountzou et al. showed that
GPI-anchored cytokines engineered onto VLPs based on simianimmunodeﬁciency virus (SIV) can be used to enhance immunogeni-
city of the VLPs in immunisation studies.
Kueng et al. (2007) used the GSS of the human low afﬁnity FcγIII
receptor CD16b to construct GPI-anchored forms of interleukins (IL)
such as IL2, IL4, IL7, IL15 and granulocyte-macrophage colony
stimulating factor (GM-CSF) (see Table 1) and found that the cytokines
genetically engineered for GPI anchoring are preferentially incorpo-
rated into VLPs based on expression of Moloney MLV (MoMLV) gagpol
constructs in the human embryonal kidney cell line, HEK293.
Additionally, they could demonstrate that incorporation into the VLP
is dependent on the type of membrane association displayed by the
cytokines i.e. GPI-anchored cytokines where incorporated, whereas
cytokines fused to trans-membrane domains were not. This is
evidence for the co-localisation of viral budding and GPI-anchored
proteins and also indicates that incorporation of GPI-anchored is not
exclusively due to their over-expression in the virus producing cell
lines. GPI-anchored IL4 and GM-CSF displayed on VLPs were used to
successfully differentiate monocytes into dendritic cells in co-
cultivation experiments. Moreover, morphological and biochemical
(i.e. cytokine ﬁngerprints) hallmarks of differentiation were compar-
able to results achieved with soluble cytokines. VLPs functionalised
with GPI-anchored IL2 were used for co-stimulation of peripheral
blood mononuclear cells (PBMCs) and increased proliferation in a
dose-dependent manner was detected, again similar to results
obtained with the soluble cytokine (Kueng et al., 2007).
Skountzou et al. (2007) used a similar approach to incorporate
immune-stimulatory molecules e.g. GM-CSF into SIV-based VLPs. The
rationale was to develop VLPs suitable for vaccination purposes. HIV
vaccines usually produce a signiﬁcant cytotoxic T cell response,
however, generation of neutralizing antibodies is usually weak.
Subsequently, vaccines prolong survival in primates but protective
immunity, i.e. prevention of infection, is not achieved. Incorporation of
immune-stimulatory factors into viral antigen carrying VLPs is one
strategy to generate vaccines with increased efﬁcacy. VLPs displaying
GPI-anchored GM-CSF were produced in insect cells and used to test
immunological response in vitro and in vivo. Chimeric VLPs did indeed
increase activation of B cells and generally induced enhanced humoral
immune responses. Interestingly, incorporation of fusion proteins of
GM-CSF containing the trans-membrane domain of the HIV gp160
(instead of a GPI anchor) into VLPs did not increase immune responses
in mice, although localisation of the fusion protein to the cell
129Minireviewmembrane was observed and the fusion protein was functional.
Incorporation of the fusion protein was achieved, however, with less
efﬁciency than the GPI-anchored form, indicating that incorporation is
not solely a consequence of over-expression. The incorporation levels
of recombinant GPI-anchored GM-CSF were somewhat similar to the
levels of Env proteins found in viral particles. Taken together, these
results suggest that recombinant GPI-anchored proteins can be
associated with viral particles with high efﬁciency.
Protein engineering of retroviral vectors using GPI-anchored
proteins
Transfection of producer cell lines is not the only possibility to use
GPI-anchored proteins for modiﬁcation of RVs. As mentioned
previously one interesting feature is their “hypermobility” — the
potential to shift from cell-bound to different forms of vesicular bodies
or aggregates and vice versa. Interestingly, when the proteins are
extracted and puriﬁed from the cells they are produced in and
incubated with other cells, re-insertion takes place and localisation is
once again efﬁciently conferred to the plasmamembrane. This process
is known as cellular “painting” (Legler et al., 2005; Medof et al., 1996).
Moreover, these proteins retain their function throughout the process.
It has been suggested that painting of cells might be of therapeutic
use, for example in correcting paroxysmal nocturnal hemoglobinuria
(PNH)— a disease caused by acquiredmutations in PIGA, a component
of the GPI-anchor biosynthesis pathway, leading to complement-
mediated hemolysis due to loss of complement regulators CD59 and
CD55 by providing these factors (Sloand et al., 2004) or for the
treatment of cancer by introducing co-stimulatory proteins to tumor
cells and thereby increasing immunogenicity (McHugh et al., 1999).
We have recently described the extension of this method for the
insertion of GPI-linked proteins into viral envelopes (“viral painting”,
see Fig. 1).
We could demonstrate association of the GPI-linked protein
CD59his to viral vectors based on MLV and HIV-1 (Metzner et al.,
2008). Viral particles and afﬁnity-puriﬁed proteinwere incubated for at
least 3 h at 37 °C to facilitate insertion of the GPI-anchored proteins.
After removal of non-associated and/or endogenous protein, signals for
CD59 could only be detected when both puriﬁed GPI-linked protein
and viral particles were present. The association is speciﬁc and the
painted virus particles remain infectious after insertion of the GPI-
linked protein, albeit at reduced efﬁciencies caused predominantly by
the duration of the painting process, rather than the actual incorpora-
tion of GPI-anchored molecules into the viral envelope. Preliminary
results suggested that the amount of GPI-anchored proteins associated
with virus particles is dependent on the concentration of puriﬁed GPI
protein during incubation, allowing for insertion of different amounts
of GPI-anchored proteins into viral envelopes. Estimates of the number
of GPI-anchored proteins painted onto retroviral particles were in the
range of the numbers observed for Envmolecules per virion and is thus
similar to that achieved after incorporation of hybrid proteins
produced in co-transfection experiments (Skountzou et al., 2007).
The potential for modiﬁcation of enveloped viral vectors with
GPI-anchored proteins
Regardless of their involvement in the controversial lipid rafts, GPI-
anchored proteins appear to be exceptionally useful for the modiﬁca-
tion of retroviral vectors. Two profoundly different strategies can be
employed, each with distinct advantages: (i) transfection of viral
producer cell lines and (ii) direct protein engineeringof viral particles by
painting. Stable transfection of retroviral producer cell lines co- or
super-transfected with endogenous or recombinant GPI-anchored
proteins will provide a long-term, reliable source of modiﬁed viral
particles with high reproducibility. Recent studies using transfection
methods to express GPI-anchored proteins in virus producing cell lineshave demonstrated the usefulness of this approach to increase
immunogenicity of VLPs and in eliciting speciﬁc responses like
differentiation and proliferation from target cells upon co-cultivation.
The strength of viral painting lies in different areas than for co-
transfection approaches: The association is quick — 3 h, probably less
are sufﬁcient for maximum painting (work still in progress). The
method is very ﬂexible since different types of RV, regardless of the
transfer vectors included, can be modiﬁed. In theory, also other
enveloped viruses like hepatitis B or inﬂuenza virus can be modiﬁed,
due to the fact that afﬁnityofGPI-anchoredproteins to viral envelopes is
based on the shared lipophilicity only. Moreover, no genetic modiﬁca-
tion of producer cell lines is necessary. Finally, preliminary experiments
suggest that the amount of GPI-modiﬁed proteins on the virus is
controllable. Viral painting may be the method of choice for modiﬁca-
tion of enveloped viral particles in all circumstanceswhere (i) ﬂexibility
is required, e.g., in response to genetic heterogeneity in gene therapy
patients or in response to quickly changing antigen presentation for
vaccination, and (ii) genetic modiﬁcation of virus producing cell lines is
difﬁcult e.g.whenusing cytotoxic proteinsorwhenhandlinggenetically
and/or biochemically poorly deﬁned virus species or variants.
Using GPI-anchored proteins for modiﬁcation of enveloped viral
particles may proﬁt virology researchers in two ways. On the basic
science side, they can be helpful in elucidating the links between
membrane microdomains and virus biology and enable a better
understanding of the interactions between the virus and the host
(cell) membranes during virus entry and exit to cells. Secondly, this
type of modiﬁcation promises great potential for more applied ﬁelds,
e.g. viral gene therapy or vaccine development and may lead to
development into clinical solutions. Therefore research in this area
should be encouraged.References
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